arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

ArriVent BioPharma, Inc.

AVBP

$30.81 ▼ -0.22 (-0.71%) at close

14 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

ArriVent BioPharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -11.2% ↘

FCF / Share $-0.93

Trailing P/E —

Price / Book 4.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-43.32M

↑ +32.7% —

FCF / Share Free cash flow per share

$-0.93

↑ +53.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	49.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-27.9% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-36.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-38.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-171.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	92.1% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	88.9% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	94.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	92.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	32.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-72.3% Weak ↑ Weak Improving Year-over-year change in net income	-269.7% Weak ↓ Weak Declining Year-over-year change in net income	-269.7% Weak ↓ Weak Declining Year-over-year change in net income	-269.7% Weak ↓ Weak Declining Year-over-year change in net income	2.6% Caution ↑ Caution Improving Year-over-year change in net income	-43.1% Weak → Weak Stable Year-over-year change in net income	-43.1% Weak Weak Year-over-year change in net income	-43.1% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	53.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-169.7% Weak Weak Year-over-year change in free cash flow	—	—	—	94.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	1.07x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.27x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.39x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-9.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	11.9% Good → Good Stable Return earned on debt + equity capital invested Optimal: > 10%	10.0% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	15.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	9.9% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-13.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-14.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-13.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-189%)	-11.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-21.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-241%)	-25.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-272%)	-31.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-312%)	-8.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-153%)	-6.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-142%)	-5.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-139%)	-5.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-137%)	13.8% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-8%)	9.2% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	10.3% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-31%)	12.5% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-16%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-62.10M	$-45.54M	$-112.67M	$-112.77M	$-49.87M	$-74.29M	$-282.86M	$-298.67M	$-317.39M	$-150.39M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.96	$-0.78	$-0.83	$-0.90	$-1.90	$-0.61	$-0.61	$-0.65	$-0.70	$-7.69	$-5.52	$-10.79	$-9.45	—
Free Cash Flow per Share (USD)	$-0.93	—	$-0.85	$-0.75	$-2.01	—	—	—	$-0.74	—	$-5.92	$-4.30	$-13.11	—
Book Value per Share (USD)	$7.15	$7.24	$7.47	$6.66	$5.95	$7.64	$8.24	$8.85	$9.49	$-55.80	$-50.86	$-59.24	$-75.40	—
Tangible Book Value per Share (USD)	$7.15	$7.24	$7.47	$6.66	$5.95	$7.64	$8.24	$8.85	$9.49	$-55.80	$-50.86	$-59.24	$-75.40	—
Basic Weighted Avg Shares (shares)	45.07M	—	41.91M	35.01M	33.90M	—	33.58M	33.50M	25.05M	—	2.61M	2.00M	1.29M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$323.70M	$306.95M	$299.66M	$230.51M	$172.83M	$209.71M	$277.24M	$296.41M	$317.50M	$148.34M	—	—	—	—
Total Equity (USD)	$323.98M	$307.22M	$305.00M	$249.87M	$202.54M	$257.65M	$277.49M	$296.66M	$317.72M	$-153.19M	$-132.60M	$-118.46M	$-97.09M	$-85.11M

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Income, GAAP (USD)	$-43.32M	$-35.54M	$-64.39M	$-64.39M	$-64.39M	$-20.63M	$-17.42M	$-17.42M	$-17.42M	$-21.19M	$-12.17M	$-12.17M	$-12.17M	—
Operating Cash Flow (USD)	$-41.89M	$-30.66M	$-35.80M	$-26.12M	$-68.01M	$-16.15M	—	—	$-18.63M	$-14.91M	$-15.44M	$-8.61M	$-16.88M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

ArriVent BioPharma, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AVBP with peers